FDA Ends Expedited Review as Compass Files Psilocybin NDA
Regulatory shifts, a landmark New Drug Application, and new federal funding for ibogaine reshape the U.S. psychedelic research and approval landscape in late 2026.
FDA Ends Expedited Drug Review Program, Raising Approval Barriers
The U.S. Food and Drug Administration (FDA) has discontinued its expedited drug review program, a move that could slow the approval process for novel therapeutics including psychedelic compounds. This program, commonly referred to as 'fast track' or 'breakthrough therapy' designation, allowed sponsors to receive enhanced guidance and prioritized review for drugs addressing serious conditions with unmet medical need. The agency has not yet published a formal docket or public notice as of November 2026, but multiple sources confirm the program's closure for new applicants. Without this pathway, future sponsors of psychedelic therapies must navigate the standard, often lengthier, review process, increasing both time and resource commitments.
This change comes at a critical juncture for psychedelic medicine, as several compounds—such as psilocybin, MDMA (3,4-methylenedioxymethamphetamine), and ibogaine—have advanced into late-stage clinical development. The end of expedited review may also impact investor confidence and delay patient access, especially for conditions like treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD), where conventional options are limited. Notably, the FDA's decision does not affect drugs already granted expedited status, but it raises questions about the future regulatory landscape for novel neuropsychiatric treatments.
Compass Pathways Submits First Psilocybin NDA to FDA
Compass Pathways plc has submitted a New Drug Application (NDA) for its synthetic psilocybin formulation, COMP360, targeting treatment-resistant depression. This submission is the first of its kind for a classic psychedelic in the United States, marking a significant regulatory milestone. The NDA follows the completion of Compass's Phase 3 program (NCT05149502, NCT05466881), which evaluated COMP360 in over 1,000 participants across multiple sites in North America and Europe. While topline results have been shared in company press releases, full peer-reviewed data remain pending.
The FDA will now conduct a filing review to determine if the application is sufficiently complete for substantive evaluation. If accepted, the agency will assign a Prescription Drug User Fee Act (PDUFA) date, typically 10-12 months from acceptance, unless priority review is granted. However, with the expedited review program discontinued, COMP360 will likely undergo standard review timelines. This development provides a concrete example of how regulatory shifts can directly affect sponsors' strategic planning and market entry projections.
Federal Government Commits $25 Million for Ibogaine and Psychotropic Research
The U.S. federal government has announced a $25 million funding initiative for research on ibogaine and other psychotropic compounds. This commitment, managed by the National Institutes of Health (NIH), represents the largest single federal investment in psychedelic research to date. The funds will support preclinical and early-phase clinical trials, with a focus on substance use disorders and neuropsychiatric conditions. The NIH has issued a Notice of Funding Opportunity (NOT-DA-27-001), inviting proposals from academic and clinical research centers nationwide.
This allocation signals a shift in federal policy toward greater support for psychedelic science, moving beyond observational studies toward controlled trials. It also addresses a known failure mode in psychedelic research: the historical lack of sustained, large-scale public funding, which has limited the field's ability to generate robust safety and efficacy data. The inclusion of ibogaine—a compound with unique cardiac risks and complex legal status—suggests a willingness to engage with both the promise and the challenges of next-generation psychotropics.
Risks, Unknowns, and Implications for Stakeholders
The discontinuation of the expedited review pathway introduces new risks for sponsors, clinicians, and patients. Longer review timelines may increase development costs and delay access to potentially beneficial therapies. For compounds like ibogaine, which carry significant safety concerns (notably QT prolongation and cardiac arrhythmias), the need for rigorous, well-powered trials is acute. The $25 million federal investment may help address these gaps, but it is unlikely to fully offset the increased regulatory burden introduced by the loss of expedited review.
Stakeholders should also be aware of non-obvious implications: the end of the speedy review program may create a bottleneck for smaller sponsors lacking the resources to sustain multi-year approval processes, potentially consolidating market power among larger, well-capitalized firms. Additionally, the FDA's evolving stance underscores the importance of early and ongoing regulatory engagement, as shifting policies can rapidly alter the risk calculus for psychedelic development programs.
Looking Forward: A New Phase for Psychedelic Research and Policy
The convergence of regulatory, scientific, and funding developments in late 2026 marks an inflection point for the psychedelic field. The FDA's policy change, Compass Pathways' NDA submission, and the NIH's new funding stream collectively signal both heightened scrutiny and growing legitimacy. Researchers, sponsors, and clinicians should anticipate a period of increased regulatory complexity, but also new opportunities for rigorous investigation and collaboration. As the field adapts, transparent communication of both risks and benefits will be essential for maintaining public trust and advancing evidence-based policy.
By Dr. Alex Harper, PhD (Neuropharmacology). Reviewed by Dr. Jamie Lin, MD, on 2026-11-14. Sources: FDA Fast Track, ClinicalTrials.gov, NIH Funding Notice.
Get tomorrow's briefing in your inbox
Policy, research, and regulatory signal — delivered on our publish cadence.